BioAtla (BCAB)

• Market cap: $19.7M
• 1 day: -3.88%
• 5 days: -9.47%
• 1 month: 11.35%
• 3 months: -44.71%
• 6 months: -83.28%
• Year to date: -44.71%
• 1 year: -90.36%
• 5 years: -98.91%
• 10 years: -98.91%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Employees: 65

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

147% more call options, than puts

Call options by funds: $84K | Put options by funds: $34K

22% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 18

5.61% more ownership

Funds ownership: 35.77% [Q3] → 41.38% (+5.61%) [Q4]

5% more funds holding

Funds holding: 64 [Q3] → 67 (+3) [Q4]

16% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 19

53% less capital invested

Capital invested by funds: $30.4M [Q3] → $14.2M (-$16.2M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $1 195% upside
• Avg. target: $1 195% upside
• High target: $1 195% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Citizens Capital Markets Reni Benjamin 14% 1-year accuracy 5 / 37 met price target

195% upside $1

Market Outperform Maintained

31 Mar 2025